Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 7/20 | 0.37 |
| ▸ | MAOA | P21397 | 4/20 | 0.37 |
| ▸ | PNMT | P11086 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyamine SCHEMBL1770289 | 0.92 | LMNA (0.48) | LMNAKDM4EMEN1MAPTOPRK1 | |
| Hydrochloric Acid SCHEMBL4235155 | 0.91 | LMNA (0.48) | LMNAKDM4EMEN1MAPTOPRK1 | |
| SCHEMBL28399140 | 0.85 | LMNA (0.45) | LMNAKDM4EMEN1MAPTOPRK1 | |
| SCHEMBL28863381 | 0.81 | MEN1 (0.61) | LMNAKDM4EMEN1MAPTOPRK1 | |
| SCHEMBL21843497 | 0.81 | LMNA (0.42) | LMNAKDM4EMEN1MAPTOPRK1 | |
| SCHEMBL29860802 | 0.81 | MEN1 (0.61) | LMNAKDM4EMEN1MAPTOPRK1 | |
| SCHEMBL29392072 | 0.80 | MEN1 (0.67) | LMNAKDM4EMEN1MAPTOPRK1 | |
| SCHEMBL129053 | 0.80 | MEN1 (0.67) | LMNAKDM4EMEN1MAPTOPRK1 | |
| SCHEMBL10520863 | 0.79 | CHRM2 (0.53) | LMNAKDM4EMEN1MAPTOPRK1 | |
| SCHEMBL14122566 | 0.78 | MEN1 (0.71) | LMNAKDM4EMEN1MAPTOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090252013-A1 | HYDRAZIDE CHELATE COMPLEX COMPOUND, OPTICAL RECORDING MEDIUM USING THE COMPOUND AND RECORDING METHOD THEREOF | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-10-08 | — | — | US | disclosed |
| EP-2050794-A1 | HYDRAZIDE CHELATE COMPLEX COMPOUND, OPTICAL RECORDING MEDIUM USING THE COMPOUND AND RECORDING METHOD THEREOF | Mitsubishi Chemical Corporation (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090252013-A1 | HYDRAZIDE CHELATE COMPLEX COMPOUND, OPTICAL RECORDING MEDIUM USING THE COMPOUND AND RECORDING METHOD THEREOF | KCNN2, KCNH2, KCNN1 | LMNA 1854/4885KDM4E 748/4885MEN1 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.